The cost of antibiotic resistance depends on evolutionary history in Escherichia coli

BMC Evolutionary Biology

Volumn 13, Issue 1, 2013, Pages

  Angst, Daniel C ^a,b   Hall, Alex R ^a,b  

^a ETH ZURICH   (Switzerland)

^b Department of Environmental Microbiology ^*  (Switzerland)

Author keywords

Antibiotic resistance; Epistasis; Escherichia coli; Experimental evolution

Indexed keywords

ADAPTATION; ANTIBIOTIC RESISTANCE; EPISTASIS; EVOLUTIONARY BIOLOGY; FITNESS; GENOME; MICROBIAL ACTIVITY; MICROBIAL COMMUNITY; MUTATION; PERSISTENCE;

BACTERIA (MICROORGANISMS); ESCHERICHIA COLI;

ANTIINFECTIVE AGENT; RIFAMPICIN; STREPTOMYCIN;

ADAPTATION; ANTIBIOTIC RESISTANCE; ARTICLE; DRUG EFFECT; ESCHERICHIA COLI; EVOLUTION; GENETICS; GENOTYPE; MUTATION; PHYSIOLOGY; PLASMID;

ADAPTATION, PHYSIOLOGICAL; ANTI-BACTERIAL AGENTS; BIOLOGICAL EVOLUTION; DRUG RESISTANCE, BACTERIAL; ESCHERICHIA COLI; GENOTYPE; MUTATION; PLASMIDS; RIFAMPIN; STREPTOMYCIN;

EID: 84880898539     PISSN: None     EISSN: 14712148     Source Type: Journal    
DOI: 10.1186/1471-2148-13-163     Document Type: Article

References (51)

1. Antibiotic resistance and its cost: is it possible to reverse resistance? Andersson DI, Hughes D, Nat Rev Microbiol 2010 8 4 260 271 20208551
2. The biological cost of antibiotic resistance. Andersson DI, Levin BR, Curr Opin Microbiol 1999 2 5 489 493 10.1016/S1369-5274(99)00005-3 10508723
3. Fitness costs of fluoroquinolone resistance in Streptococcus pneumoniae. Rozen DE, McGee L, Levin BR, Klugman KP, Antimicrob Agents Chemother 2007 51 2 412 416 10.1128/AAC.01161-06 17116668
4. Initial mutations direct alternative pathways of protein evolution. Salverda ML, Dellus E, Gorter FA, Debets AJ, van der Oost J, Hoekstra RF, Tawfik DS, de Visser JA, PLoS Genet 2011 7 3 1001321 10.1371/journal.pgen.1001321 21408208
5. Positive epistasis drives the acquisition of multidrug resistance. Trindade S, Sousa A, Xavier KB, Dionisio F, Ferreira MG, Gordo I, PLoS Genet 2009 5 7 1000578 10.1371/journal.pgen.1000578 19629166
6. The cost of multiple drug resistance in Pseudomonas aeruginosa. Ward H, Perron GG, MacLean RC, J Evol Biol 2009 22 5 997 1003 10.1111/j.1420-9101.2009. 01712.x 19298493
7. Perspective: sign epistasis and genetic constraint on evolutionary trajectories. Weinreich DM, Watson RA, Chao L, Evolution 2005 59 6 1165 1174 16050094
8. Amelioration of the deleterious pleiotropic effects of an adaptive mutation in Bacillus subtilis. Cohan FM, King EC, Zawadzki P, Evolution 1994 48 1 81 95 10.2307/2410005
9. Reduction of the fitness burden of quinolone resistance in Pseudomonas aeruginosa. Kugelberg E, Lofmark S, Wretlind B, Andersson DI, J Antimicrob Chemother 2005 55 1 22 30 15574475
10. Compensatory mutations, antibiotic resistance and the population genetics of adaptive evolution in bacteria. Levin BR, Perrot V, Walker N, Genetics 2000 154 3 985 997 10757748
11. Multiple mechanisms to ameliorate the fitness burden of mupirocin resistance in Salmonella typhimurium. Paulander W, Maisnier-Patin S, Andersson DI, Mol Microbiol 2007 64 4 1038 1048 10.1111/j.1365-2958.2007.05713.x 17501926
12. Compensatory evolution in rifampin-resistant Escherichia coli. Reynolds MG, Genetics 2000 156 4 1471 1481 11102350
13. Adaptation to the fitness costs of antibiotic resistance in Escherichia coli. Schrag SJ, Perrot V, Levin BR, Proc R Soc Lond B Biol Sci 1997 264 1386 1287 1291 10.1098/rspb.1997.0178
14. Pervasive sign epistasis between conjugative plasmids and drug-resistance chromosomal mutations. Silva RF, Mendonça SC, Carvalho LM, Reis AM, Gordo I, Trindade S, Dionisio F, PLoS Genet 2011 7 7 1002181 10.1371/journal.pgen.1002181 21829372
15. Darwinian evolution can follow only very few mutational paths to fitter proteins. Weinreich DM, Delaney NF, DePristo MA, Hartl DL, Science 2006 312 5770 111 114 10.1126/science.1123539 16601193
16. Diminishing returns epistasis among beneficial mutations decelerates adaptation. Chou HH, Chiu HC, Delaney NF, Segrè D, Marx CJ, Science 2011 332 6034 1190 1192 10.1126/science.1203799 21636771
17. Negative epistasis between beneficial mutations in an evolving bacterial population. Khan AI, Dinh DM, Schneider D, Lenski RE, Cooper TF, Science 2011 332 6034 1193 1196 10.1126/science.1203801 21636772
18. Reciprocal sign epistasis between frequently experimentally evolved adaptive mutations causes a rugged fitness landscape. Kvitek DJ, Sherlock G, PLoS Genet 2011 7 4 1002056 10.1371/journal.pgen.1002056 21552329
19. The molecular diversity of adaptive convergence. Tenaillon O, Rodríguez-Verdugo A, Gaut RL, McDonald P, Bennett AF, Long AD, Gaut BS, Science 2012 335 6067 457 461 10.1126/science.1212986 22282810
20. Molecular mechanisms of antibacterial multidrug resistance. Alekshun MN, Levy SB, Cell 2007 128 6 1037 1050 10.1016/j.cell.2007.03.004 17382878
21. Compensatory evolution reveals functional interactions between ribosomal proteins S12 L14 and L19. Maisnier-Patin S, Paulander W, Pennhag A, Andersson DI, J Mol Biol 2007 366 1 207 215 10.1016/j.jmb.2006.11.047 17157877
22. Identification and functional characterization of the protein controlled by the streptomycin-resistant locus in E. coli. Ozaki M, Mizushima S, Nomura M, Nature 1969 222 5191 333 339 10.1038/222333a0 4181187
23. Complete nucleotide sequence and gene organization of the broad-host-range plasmid RSF1010. Scholz P, Haring V, Wittmann-Liebold B, Ashman K, Bagdasarian M, Scherzinger E, Gene 1989 75 2 271 288 10.1016/0378-1119(89) 90273-4 2653965
24. Genotype-by-environment interactions due to adaptation and antibiotic resistance in Escherichia coli. Hall AR, J Evol Biol 2013 10.1111/jeb.12172
25. Use of the rpoB gene to determine the specificity of base substitution mutations on the Escherichia coli chromosome. Garibyan L, Huang T, Kim M, Wolff E, Nguyen A, Nguyen T, Diep A, Hu KB, Iverson A, Yang HJ, et al. DNA Repair 2003 2 5 593 608 10.1016/S1568-7864(03)00024-7 12713816
26. E. coli genome manipulation by P1 transduction. Thomason LC, Costantino N, Court DL, Curr Protoc Mol Biol 2007 1.17 1 8
27. One-step preparation of competent Escherichia coli: transformation and storage of bacterial cells in the same solution. Chung CT, Niemela SL, Miller RH, Proc Natl Acad Sci U S A 1989 86 7 2172 2175 10.1073/pnas.86.7.2172 2648393
28. Selection of resistant bacteria at very low antibiotic concentrations. Gullberg E, Cao S, Berg OG, Ilbäck C, Sandegren L, Hughes D, Andersson DI, PLoS Pathog 2011 7 7 1002158 10.1371/journal.ppat.1002158 21811410
29. Long-term experimental evolution in Escherichia coli 1. Adaptation and divergence during 2,000 generations. Lenski RE, Rose MR, Simpson SC, Tadler SC, Am Nat 1991 138 6 1315 1341 10.1086/285289
30. Endosymbiotic bacteria-GroEL buffers against deleterious mutations. Fares MA, Ruiz-González MX, Moya A, Elena SF, Barrio E, Nature 2002 417 6887 398 10.1038/417398a 12024205
31. Proteome-wide analysis of chaperonin-dependent protein folding in Escherichia coli. Kerner MJ, Naylor DJ, Ishihama Y, Maier T, Chang HC, Stines AP, Georgopoulos C, Frishman D, Hayer-Hartl M, Mann M, et al. Cell 2005 122 2 209 220 10.1016/j.cell.2005.05.028 16051146
32. Chaperonin overexpression promotes genetic variation and enzyme evolution. Tokuriki N, Tawfik DS, Nature 2009 459 668 675 10.1038/nature08009 19494908
33. Between genotype and phenotype: protein chaperones and evolvability. Rutherford SL, Nat Rev Genet 2003 4 4 263 274 10.1038/nrg1041 12671657
34. Genomic buffering mitigates the effects of deleterious mutations in bacteria. Maisnier-Patin S, Roth JR, Fredriksson A, Nyström T, Berg OG, Andersson DI, Nat Genet 2005 37 12 1376 1379 10.1038/ng1676 16273106
35. Epistasis buffers the fitness effects of rifampicin-resistance mutations in Pseudomonas aeruginosa. Hall AR, MacLean RC, Evolution 2011 65 2370 2379 10.1111/j.1558-5646.2011.01302.x 21790582
36. The evolution of the heat-shock protein GroEL from Buchnera, the primary endosymbiont of aphids, is governed by positive selection. Fares MA, Barrio E, Sabater-Munoz B, Moya A, Mol Biol Evol 2002 19 7 1162 1170 10.1093/ oxfordjournals.molbev.a004174 12082135
37. The stability effects of protein mutations appear to be universally distributed. Tokuriki N, Stricher F, Schymkowitz J, Serrano L, Tawfik DS, J Mol Biol 2007 369 5 1318 1332 10.1016/j.jmb.2007.03.069 17482644
38. Selection for chaperone-like mediated genetic robustness at low mutation rate: impact of drift, epistasis and complexity. Gros PA, Tenaillon O, Genetics 2009 182 2 555 564 10.1534/genetics.108.099366 19307609
39. Perspective: evolution and detection of genetic robustness. de Visser JA, Hermisson J, Wagner GP, Ancel Meyers L, Bagheri-Chaichian H, Blanchard JL, Chao L, Cheverud JM, Elena SF, Fontana W, et al. Evolution 2003 57 9 1959 1972 14575319
40. Wagner A, Robustness and evolvability in living systems Princeton: Princeton University Press 2005
41. Selection for robustness in mutagenized RNA viruses. Sanjuán R, Cuevas JM, Furió V, Holmes EC, Moya A, PLoS Genet 2007 3 6 93 10.1371/journal.pgen.0030093 17571922
42. Structural mechanism for rifampicin inhibition of bacterial RNA polymerase. Campbell EA, Korzheva N, Mustaev A, Murakami K, Nair S, Goldfarb A, Darst SA, Cell 2001 104 6 901 912 10.1016/S0092-8674(01)00286-0 11290327
43. Antimicrobial drug resistance affects broad changes in metabolomic phenotype in addition to secondary metabolism. Derewacz DK, Goodwin CR, McNees CR, McLean JA, Bachmann BO, Proc Natl Acad Sci U S A 2013 110 6 2336 2341 10.1073/pnas.1218524110 23341601
44. Uncovering new metabolic capabilities of Bacillus subtilis using phenotype profiling of rifampin-resistant rpoB mutants. Perkins AE, Nicholson WL, J Bacteriol 2008 190 3 807 814 10.1128/JB.00901-07 17644585
45. Antibiotic resistance and stress in the light of Fisher's model. Trindade S, Sousa A, Gordo I, Evolution 2012 66 3815 3824 10.1111/j.1558-5646.2012. 01722.x 23206139
46. Evolution of Escherichia coli rifampicin resistance in an antibiotic-free environment during thermal stress. Rodríguez-Verdugo A, Gaut BS, Tenaillon O, BMC Evol Biol 2013 13 50 10.1186/1471-2148-13-50 23433244
47. Long-term experimental evolution in Escherichia coli. III. Variation among replicate populations in correlated responses to novel environments. Travisano M, Lenski RE, Evolution 1995 49 189 200 10.2307/2410304
48. Genetic adaptation of Pseudomonas aeruginosa during chronic lung infection of patients with cystic fibrosis: strong and weak mutators with heterogeneous genetic backgrounds emerge in mucA and/or lasR mutants. Ciofu O, Mandsberg LF, Bjarnsholt T, Wassermann T, Høiby N, Microbiology 2010 156 1108 1119 10.1099/mic.0.033993-0 20019078
49. Parallel evolution in Pseudomonas aeruginosa over 39,000 generations in vivo. Huse HK, Kwon T, Zlosnik JE, Speert DP, Marcotte EM, Whiteley M, MBio 2010 1 4 00199 10 20856824
50. Genetic adaptation by Pseudomonas aeruginosa to the airways of cystic fibrosis patients. Smith EE, Buckley DG, Wu Z, Saenphimmachak C, Hoffman LR, D'Argenio DA, Miller SI, Ramsey BW, Speert DP, Moskowitz SM, et al. Proc Natl Acad Sci U S A 2006 103 22 8487 8492 10.1073/pnas.0602138103 16687478
51. Whole-genome sequencing of rifampicin-resistant Mycobacterium tuberculosis strains identifies compensatory mutations in RNA polymerase genes. Comas I, Borrell S, Roetzer A, Rose G, Malla B, Kato-Maeda M, Galagan J, Niemann S, Gagneux S, Nat Genet 2012 44 1 106 112